Abstract
The biology of human renal cell carcinoma (RCC) has long been considered to be influenced by the immune system of the tumor host. The observation of occasional spontaneous regression of metastases, their erratic growth, or their occasional late occurrence following nephrectomy were thought to be strong clinical arguments for this assumption. Ljunggren et al. (1959), reporting on a case of histologically proven spontaneous regression of lung metastases, already suggested “antibody actions” as a possible explanation for such a phenomenon. Although these clinical findings are exceedingly rare and in many cases not substantiated by histology, there is definite proof that spontaneous regression of lung metastases, rather than those at other organ sites, occurs in RCC.
Keywords
- Renal Cell carCllloma
- Renal Carcinoma
- Spontaneous Regression
- Autologous Tumor Cell
- Human Renal Cell Carcinoma
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ackermann R (1975) Tumor-associated antibodies against renal cell carcinomas detected by immunofluorescence. Eur Urol 1: 154–156
Askonas BA, Rhodes JM (1965) Immunogenicity of antigen-containing ribonucleic acid preparations from macrophages. Nature 205, 470–474
Bander NH, Whitmore WF, Old LJ (1983) Monoclonal antibody defined cell surface antigens of human renal cancer. 78th Meeting of the American Urological Association, Las Vegas, p 114
Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF, Vaughan ED, Oettgen HF, Melamed M, Old L (1985) Immunohistological dissection of the human kidney using monoclonal antibodies. J Urol 133: 502–505
Belitsky P, Ghose T, Aquino J, Norvell ST, Blair AH (1978a) Radionuclide imaging of primary renal cell carcinoma by 1–131-labelled antitumor antibody. J Nucl Med 19: 427–430
Belitsky P, Ghose T, Aquino J, Tai J, MacDonald AS (1978b) Radionuclide imaging of metastases from renal-cell carcinoma by 131–1-labelled antitumor antibody. Radiology 126: 515–517
Bichler KH, Ax W, Tautz CH (1975) Cell-mediated immunity in patients with renal adenocarcinoma. Eur Urol 1: 231–234
Brosman S, Hausman M, Shacks S (1975) Studies on the immune status of patients with renal adenocarcinoma. J Urol 114: 375–380
Bubenik J, Jakoubkova J, Krakora P, Baresova M, Helbich P, Viklicky Y, Malaskova V (1971) Cellular immunity to renal carcinomas in man. Int J Cancer 8: 503–513
Cheever MA, Greenberg PD, Fefer A (1980) Therapy of leukemia by nonimmune syngeneic spleen cells. J Immunol 124: 2137–2142
Cole AT, Avis I, Fried FA, Avis F (1976) Cell-mediated immunity in renal cell carcinoma - preliminary report. J Urol 115: 234–238
Cummings KH, Peter JB, Kaufman J J (1973) Cell-mediated immunity to tumor antigens in patients with renal cell carcinoma. J Urol 110: 31–35
Cummings KH, Peter JB, Kaufman JJ (1974) Cytotoxic serum factors in patients with renal cell carcinoma. J Urol 111: 330–333
Daly JJ, Prout GR, Ahl CA, Lin JC (1974) Specificity of cellular immunity to renal cell carcinoma. J Urol 111: 448–452
DeKernion JB (1983) Treatment of advanced renal cell carcinoma — traditional methods and innovative approaches. J Urol 130: 2–7
DeKernion JB, Ramming KP, Gupta RK (1979) The detection and clinical significance of antibodies to tumor-associated antigens in patients with renal cell carcinoma. J Urol 122: 300–305
Elhilali MM, Nayak S (1975) Immunologic evaluation of human renal cell carcinoma. Invest Urol 13: 60–66
Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF, Melamed MR, Old LJ (1985) Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 82: 2955–2959
Fowler JE (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135: 22–25
Garnick B, Reich SD, Richie JP (1986) Phase I/II study of recombinant interferon gamma (Immuneron TM) in advanced renal cell carcinoma (RCC). 81st Annual meeting of the American Urological Association (abstract no. 250). J Urol 135: 166 A
Hakala TR, Castro AE, Elliott A, Fraley E (1974) Humoral cytotoxicity in human renal cell carcinoma. Invest Urol 11: 405–410
Haller O, Hanson M, Kiessling R, Wigzell H (1977) Role of non-conventional natural killer cells in resistance against syngeneic tumor cells in vivo. Nature 270: 609–611
Hellström I, Hellström KE, Sjögren HO, Warner GA (1971) Demonstration of cell-mediated immunity to human neoplasms of various histologic types. Int J Cancer 7: 1–16
Hemstreet GP, Dawson JR, Seigler HF (1978) Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma. Cancer Res 38: 1447–1456
Hess H, Alheid U, Biermann S, Waks T, Scherberich JE, Mondorf AW, Schoeppe W, Senge T, Falkenberg FW (1982) Preparation and characterization of monoclonal antibodies against antigens of human renal adenocarcinoma. In: Peeters H (ed) Protides of the biological fluids, 29th colloquium 1981. Pergamon, Oxford, pp 903–905
Jürgenliemk I, Senge T, Scherberich JE, Falkenberg FW (1983) Detection of different morphological structures in human kidneys and kidney carcinomas by monoclonal antibodies. Immunobiol 165: 288
Kasai M, Leclerc JC, McVai-Boudreau L, Shen FW, Cantor H (1979) Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med 149: 1260–1264
Kirkwood JM, Harris JE, Vera R, Sandler S (1983) Randomized trial of two doses of leucocyte interferon in metastatic renal cell carcinoma. The American Society Collaborative Trial. In: Proceedings ASCO, Abstract 579, San Diego
Kjaer M (1974) In vitro demonstration of cellular hyper-sensitivity to tumor antigens by means of leucocyte migration technique in patients with renal carcinoma. Eur J Cancer 10: 523–531
Kjaer M (1975) The dose-related effect of tumor extract on the in vitro migration of leucocytes from patients with renal carcinoma. Eur J Cancer 11: 281–289
Kjaer M, Thomsen M (1976) General immunocompetence and tumor-directed, cell-mediated hypersensitivity in vitro in patients with renal carcinoma. Acta Pathol Microbiol Scand (C) 84: 403–413
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497
Ljunggren E, Holm S, Karth B, Pompeius R (1959) Some aspects of renal tumors with special reference to spontaneous regression. J Urol 82: 553–557
McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma. Cancer 47: 1984–1987
Minton JP, Pennline K, Nowrocki JF (1976) Immunotherapy of human kidney cancer. Proc Am Soc Clin Oncol 17: 301
Montie JE, Straffon RA, Deodhar SD, Barna B (1976) In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J Urol 115: 239–242
Montie JE, Bukowski R, Deodhar S, Hewlett J, Stewart B, Straffon R (1977) Immunotherapy of disseminated renal cell carcinoma with transfer factor. J Urol 117: 553–554
Morales A, Eidinger D (1976) Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol 115: 377–380
Morales A, Wilson JL, Pater JL, Loeb M (1982) Cytoreductive surgery and systemic Bacillus Calmette-Guerin therapy in metastatic renal cancer: A phase II trial. J Urol 127: 230–235
Nairn RC, Philip J, Ghose T, Porteous IB, Fothergill JE (1963) Production of a precipitin against renal cancer. Br Med J 1: 1702–1704
Nakano E, Tada Y, Ichikawa Y, Fujioka H, Ishibasi M, Matsuda M, Takaha M, Sonoda T (1985) Cytotoxic activity of peripheral blood lymphocytes grown with interleukin 2 against autologous cultured tumor cells in patients with renal cell carcinoma. Preliminary Report. J Urol 134: 24–28
Neidhart JA, Murphy SG, Hennick LA, Wise HA (1980) Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 46: 1128–1134
Oosterwijk E, Fleuren GJ, Jonas U, Zwartendijk J, te Velde J, Warnaar SO (1984) The expression of renal antigens in renal cell carcinoma. J Urol 2: 156–158
Otto U, Huland H, Denkhaus H, Klosterhalfen H (1986) Therapie mit rekombinantem Alpha-2 oder rekombinantem Gamma-Interferon bei Patienten mit metastasierendem Nierenkarzinom. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 37. Tagung (1985). Thieme, Stuttgart
Pappas A, Schwarze G (1974) In vitro demonstration of cell-mediated immunity against human renal cell carcinoma assessed by the leucocyte migration assay. Z Immunitaetsforsch 148: 142–150
Prehn RT, Main JM (1957) Immunity to methyleholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769
Queseda JR, Swanson DA, Trinoka A, Gutterman JK (1983) Renal cell carcinoma: anti-tumor effects of leucocyte interferon. Cancer Res 43: 940–947
Ravitz G, Watne AL, Milam DF (1972) Autoantibodies to human renal cell carcinoma. J Urol 107: 26–28
Retsas S, Priestman TJ, Newton KA (1983) Treatment of metastatic renal cell carcinoma with human lymphoblastoid interferon. A phase-II study. In: Proceedings ASCO, Abstract C-515, San Diego
Richie JP, Wang BS, Steele GD, Wilson RE, Mannick J A (1981) In vivo and in vitro effects of xenogeneic immune ribonucleic acid in patients with advanced renal cell carcinoma: a phase I study. J Urol 126: 24–28
Scharfe T, Becht E, Kaltwasser R, Thiiroff JW, Jacobi GH, Hohenfellner R (1985) Tumor-specific monoclonal antibodies for renal cell carcinoma. Eur Urol 11: 1176–1120
Scharfe T, Becht E, Klippel KF, Jacobi GH, Hohenfellner R (1986) Active immunotherapy of stage IV renal cell cancer using autologous tumor cells. W J Urol 3: 245–248
Scherberich J, Hess H, Alheid U, Falkenberg F, Mondorf W, Schoeppe W (1983) Immunological studies on membrane associated antigens from renal adenocarcinoma and human kidney cortex using poly- and monoclonal antibodies. In: Peeters H (ed) Protides of the biological fluids, proceedings of the 30th colloquium. Pergamon, Oxford
Skinner DG, DeKernion JB, Brower PA, Ramming KP, Pilch Y (1976) Advanced renal cell carcinoma: Treatment with xenogeneic immune ribonucleic acid and appropriate surgical resection. J Urol 115: 246–250
Stjernsward J, Almgard LE, Franzen S, Schreeb von T, Wadstrom LB (1970) Tumor-distinctive cellular immunity to renal carcinoma. Clin Exp Immunol 6: 963–968
Takasugi M, KLein E (1971) The methodology of microassay for cell-mediated immunity (MCI) In: Bloom BR, Glade PR (eds) In vitro methods in cell-mediated immunity. Academic, New York
Takasugi M, Mickey MR, Terasaki PI (1973) Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res 33: 2898–2902
Tallberg T, Tykka H, Mahlberg K, Halttunen P, Lehtonen T, Kalima T, Sarna S (1985) Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma patients. A thirteen-year follow-up study. Eur Urol 11: 233–243
Talmadge JE, Meyers KM, Prieur DJ, Starkey JR (1980) The role of NK cells in tumor growth and metastasis in beige mice. Nature 284: 622–624
Tykkä H (1981) Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study. Scand J Urol Nephrol (Suppl) 63: 7–107
Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Li LTC, Whitmore WF, Oettgen HF, Old LJ (1979) Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 150: 565–579
Ueda R, Ogata SI, Morrissey DM, Finstad CL, Szkudlarek J, Whitmore WF, Oettgen HF, Lloyd KO, Old LJ (1983) Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: Identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci USA 78: 5122–5126
White RG (1974) Workshop report. In: Brent L, Holborow J (eds) Progress in immunology II. North Holland, Amsterdam, vol 2, p 385
Wright GL, Schellhammer PF, Faulconer R (1977) Isolation of a soluble tumor-associated antigen from human renal cell carcinoma by gradient acrylamide gel electrophoresis. Cancer Res 37: 4228–4232
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ackermann, R. (1987). Immunologic Aspects of Malignant Renal Disease. In: Löhr, E., Leder, LD. (eds) Renal and Adrenal Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71207-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-71207-4_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71209-8
Online ISBN: 978-3-642-71207-4
eBook Packages: Springer Book Archive